These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 17764756)

  • 1. Novel therapeutic targets for enteric nervous system disorders.
    De Giorgio R; Barbara G; Furness JB; Tonini M
    Trends Pharmacol Sci; 2007 Sep; 28(9):473-81. PubMed ID: 17764756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic receptors in therapeutic approaches to gastrointestinal disorders.
    Neal KB; Bornstein JC
    Curr Opin Pharmacol; 2006 Dec; 6(6):547-52. PubMed ID: 16973419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs acting on serotonin receptors for the treatment of functional GI disorders.
    Tonini M; Pace F
    Dig Dis; 2006; 24(1-2):59-69. PubMed ID: 16699264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin and its role in colonic function and in gastrointestinal disorders.
    Costedio MM; Hyman N; Mawe GM
    Dis Colon Rectum; 2007 Mar; 50(3):376-88. PubMed ID: 17195902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
    Gershon MD; Tack J
    Gastroenterology; 2007 Jan; 132(1):397-414. PubMed ID: 17241888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacotherapy of gastrointestinal motor disorders.
    Schuurkes JA
    Rev Gastroenterol Mex; 1994; 59(2):165-70. PubMed ID: 7991970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic targets].
    Bueno L
    Gastroenterol Clin Biol; 2009 Feb; 33 Suppl 1():S59-67. PubMed ID: 19303540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin and its implication for the management of irritable bowel syndrome.
    Gershon MD
    Rev Gastroenterol Disord; 2003; 3 Suppl 2():S25-34. PubMed ID: 12776000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders.
    Sanger GJ; Lee K
    Nat Rev Drug Discov; 2008 Mar; 7(3):241-54. PubMed ID: 18309313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity.
    Bueno L; de Ponti F; Fried M; Kullak-Ublick GA; Kwiatek MA; Pohl D; Quigley EM; Tack J; Talley NJ
    Neurogastroenterol Motil; 2007 Jan; 19(1 Suppl):89-119. PubMed ID: 17280587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-hydroxytryptamine and the gastrointestinal tract: where next?
    Sanger GJ
    Trends Pharmacol Sci; 2008 Sep; 29(9):465-71. PubMed ID: 19086255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathophysiological concepts of functional dyspepsia and irritable bowel syndrome future pharmacotherapy.
    Dobrek Ł; Thor PJ
    Acta Pol Pharm; 2009; 66(5):447-60. PubMed ID: 19894640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The enteric nervous system: normal functions and enteric neuropathies.
    Furness JB
    Neurogastroenterol Motil; 2008 May; 20 Suppl 1():32-8. PubMed ID: 18402640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gastrointestinal motility disorders and drugs: opioids, calcium antagonists, nitrates, peptides, prostaglandins and 5-hydroxytryptaminergic drugs (part II)].
    Jovanović-Mićić D; Samardzić R; Beleslin B
    Srp Arh Celok Lek; 1994; 122(3-4):88-92. PubMed ID: 17972818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Irritable bowel syndrome: pathophysiology and (future) treatment options].
    de Schryver AM; Samsom M
    Ned Tijdschr Geneeskd; 2002 Jan; 146(1):12-7. PubMed ID: 11802330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tachykinin receptors as drug targets for motility disorders.
    Hoogerwerf WA; Sarna SK
    Dig Dis; 2006; 24(1-2):83-90. PubMed ID: 16699266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.
    Camilleri M
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():40-5. PubMed ID: 17620087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity.
    Greenwood-van Meerveld B
    Neurogastroenterol Motil; 2007 Aug; 19 Suppl 2():13-8. PubMed ID: 17620083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin pharmacology in the gastrointestinal tract: a review.
    Beattie DT; Smith JA
    Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):181-203. PubMed ID: 18398601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.